Project Grant R21CA309450
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $405K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Cancer Institute awarded the University of California, Los Angeles $653,568 on July 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to conduct research on enhancing antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The research addresses a bottleneck in immunotherapy: naturally occurring T cells targeting tumor-associated antigens or neoantigens often exhibit low to intermediate affinity and weak antitumor activity, and...
- The National Cancer Institute awarded Duke University $509,581 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to conduct research on innate immune memory for glioma immunotherapy. The research investigates how to enhance the antitumor efficacy of PVSRIPO, a live-attenuated recombinant poliovirus, in patients with recurrent glioblastoma. Clinical trials showed that intratumoral PVSRIPO infusion achieved long-term survival in approximately 20 percent of recurrent...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The research program will expose glioblastoma neurosphere models to 3,792 small...
- The National Cancer Institute awarded Northwestern University $496,357 under the Cancer Treatment Research program (CFDA 93.395) on April 17, 2026, to investigate mechanisms of immunosuppression in glioblastoma and develop therapeutic interventions targeting tumor-associated macrophage polarization. The research centers on the peri-necrotic niche within IDH-wildtype glioblastoma tumors, where hypoxic glioma cells and immunosuppressive tumor-associated macrophages aggregate in spatial...
- The National Institutes of Health National Cancer Institute awarded The Washington University $645,185 under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, to develop and test a combination immunotherapy approach for glioblastoma. The recipient will conduct research on an "expand and pull" strategy combining long-acting interleukin-7 (IL-7) with oncolytic virus therapy to expand peripheral CD8+ T cells and recruit them into the glioblastoma tumor microenvironment....
- The National Institute of Neurological Disorders and Stroke awarded The Regents of the University of California, San Francisco $943,253 on January 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders grant program (CFDA 93.853, Assistance Listing R35NS142982). The award funds preclinical development of breakthrough immunotherapy for brain tumors, specifically malignant glioma. Research activities include developing neo-junction-targeting T-cell...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute awarded the University of California, San Diego $650,597 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of B cells in durable complete responses to checkpoint blockade immunotherapy in head and neck squamous cell carcinoma. The project addresses the mechanisms underlying exceptional responses to immunotherapy in a subset of head and neck cancer patients who achieve durable complete responses and remain...
- The National Cancer Institute awarded The Ohio State University $567,754 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on immunotherapy for glioblastoma by targeting an immunoregulatory neuropeptide. The research addresses glioblastoma (GBM), the most lethal primary brain tumor, which exhibits remarkable resistance to immunotherapy due to CD8 T cell exclusion and dysfunction driven by immunosuppressive myeloid cells, particularly tumor-associated...